Critical Illness — Prospective National Survey of the Palliative Situation Among Inmates in French Prisons
Citation(s)
AUBRY R , 2011, Etat des lieux du développement des soins palliatifs en France en 2010, Rapport à M. Le Président de la République, M. Le Premier Ministre, Comité national de suivi du développement des soins palliatifs.
Gallagher EM Elders in prison. Health and well-being of older inmates. Int J Law Psychiatry. 2001 Mar-Jun;24(2-3):325-33.
Kiel RA Caring for terminally ill inmates: on-site hospice care or compassionate release? Correctcare. 1995 Jun-Jul;9(2):5, 13-14.
Lin J, Mathew P Prison inmates and palliative care. JAMA. 2007 Dec 5;298(21):2481; author reply 2481.
Lincoln A Improving the conditions of confinement. End-of-life care in prison. Pharos Alpha Omega Alpha Honor Med Soc. 2008 Autumn;71(4):18-25.
Linder JF, Meyers FJ Palliative care for prison inmates: "don't let me die in prison". JAMA. 2007 Aug 22;298(8):894-901.
Lum KL Palliative care behind bars: the New Zealand prison hospice experience. J Pain Palliat Care Pharmacother. 2003;17(3-4):131-8; discussion 139-40.
Mahon NB Introduction: death and dying behind bars--cross-cutting themes and policy imperatives. J Law Med Ethics. 1999 Fall;27(3):213-5.
Mara CM Expansion of long-term care in the prison system: an aging inmate population poses policy and programmatic questions. J Aging Soc Policy. 2002;14(2):43-61.
MOUQUET M-C, DUMONT M , BONNEVIE M-C, 1999 (janvier)" La santé à l'entrée en prison, un cumul des facteurs de risques ", Études et résultats, n°4, DREES.
O'Connor MF Finding boundaries inside prison walls: case study of a terminally ill inmate. Death Stud. 2004 Jan;28(1):63-76.
Ratcliff M, Craig E The GRACE Project: Guiding End-of-Life Care in Corrections 1998-2001. J Palliat Med. 2004 Apr;7(2):373-9.
Reeder D, Meldman L Conceptualizing psychosocial nursing in the jail setting. J Psychosoc Nurs Ment Health Serv. 1991 Aug;29(8):40-4.
SANDO ROY (de) B , 2004 (mars), " La suspension de peine pour raison médicale : Une parenthèse de la peine contre une parenthèse de la santé. ", Droit Déontologie & Soin.; 4(1), pp 4-15.
SANNIER O, MANALOUIL C , 2008, " Est-ce que le secret médical est la clé de voûte du respect de l'éthique médicale en prison ? ", Éthique & Santé; 5(4), pp201-207.
Snow T Should dying prisoners be given their freedom for a more dignified end? Nurs Stand. 2009 Aug 26-Sep 1;23(51):12-3.
Turner M, Barbarachild Z, Kidd H, Payne S How notorious do dying prisoners need to be to receive high quality end-of-life care? Int J Palliat Nurs. 2009 Oct;15(10):472-3.
Vesely R Another aging population. More states considering early-release programs for older, infirm inmates. Mod Healthc. 2010 Mar 29;40(13):32-3.
Wilford T Developing effective palliative care within a prison setting. Int J Palliat Nurs. 2001 Nov;7(11):528-30.
Wood FJ The challenge of providing palliative care to terminally ill prison inmates in the UK. Int J Palliat Nurs. 2007 Mar;13(3):131-5. Review.
Zelaya E The challenges of caring for an incarcerated patient. Am J Hosp Palliat Care. 2009 Jun-Jul;26(3):230-1. doi: 10.1177/1049909109333931.
ZIMMERAMANN N , WALD F.S., THOMPSON A.S., 2002 (juillet), " The needs and ressources for hospice care in the connecticut prison system : a feasibility study. ", Illness, Crisis and Cross, vol 10, n°3, pp204-232.
Prospective National Survey of the Palliative Situation Among Inmates in French Prisons
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
